{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:34:02Z","timestamp":1758944042840},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrclinonc.2014.216","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T10:41:53Z","timestamp":1418726513000},"page":"71-72","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Improved understanding of disease biology and treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"BFnrclinonc2014216_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G.  et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2014216_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V.  et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2014216_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"156","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V.  et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 156, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2014216_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L.  et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2014216_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd, J. C.  et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213\u2013223 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2014216_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R.  et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2014216_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede, V.  et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101\u20131110 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2014216_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann, R.  et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J. Clin. Oncol. 32, 415\u2013422 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2014216_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford, S.  et al. Prognosis for patients with CML and >10% BCR\u2013ABL1 after 3 months of imatinib depends on the rate of BCR\u2013ABL1 decline. Blood 124, 511\u2013518 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2014216_CR10","first-page":"a254","volume":"122","author":"S Branford","year":"2013","unstructured":"Branford, S.  et al. Any BCR\u2013ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months [abstract]. Blood 122, a254 (2013).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.216","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:26:13Z","timestamp":1684466773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2014.216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrclinonc2014216"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2014.216","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]},"assertion":[{"value":"16 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.S.-M. has acted in a consultancy or advisory capacity for Bristol\u2013Myers Squibb, Celgene, Janssen, Millennium, MSD, Novartis and Onyx. H.M.K. has received research grants from Amgen, ARIAD, Bristol\u2013Myers Squibb, Novartis and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}